论文部分内容阅读
目的探讨培美曲塞联合顺铂治疗非小细胞肺癌的临床疗效和不良反应。方法将就诊的86例非小细胞肺癌患者随机分为观察组(43例)和对照组(43例),观察组患者采用培美曲塞联合顺铂化疗,对照组患者采用吉西他滨联合顺铂化疗。观察比较两种治疗方案的临床疗效及不良反应。结果观察组与对照组的近期疗效相当,但观察组非鳞癌患者的总有效率明显高于鳞癌患者(P<0.05);观察组患者的恶心呕吐、皮疹、口腔黏膜炎、贫血、心电图异常、肝肾功能损害等不良反应发生率与对照组相近,但观察组患者的白细胞下降、粒细胞减少、血小板降低、脱发等不良反应发生率明显低于对照组(P<0.05)。结论培美曲塞联合顺铂治疗非小细胞肺癌安全可靠,尤其适用于非鳞癌化疗。
Objective To investigate the clinical efficacy and adverse reactions of pemetrexed combined with cisplatin in the treatment of non-small cell lung cancer. Methods 86 patients with non-small cell lung cancer were randomly divided into observation group (43 cases) and control group (43 cases). The patients in the observation group were treated with pemetrexed combined with cisplatin and the control group received gemcitabine combined with cisplatin . Observed and compared the clinical efficacy and adverse reactions of the two treatment options. Results The observation group and the control group had similar curative effect in the short term, but the total effective rate in observation group was significantly higher than that in squamous cell carcinoma (P <0.05). The observation group had nausea and vomiting, rash, oral mucositis, anemia, electrocardiogram Abnormalities, liver and kidney dysfunction and other adverse reactions similar to the incidence of adverse reactions, but the observation group patients with leukopenia, neutropenia, thrombocytopenia, hair loss and other adverse reactions was significantly lower than the control group (P <0.05). Conclusion Pemetrexed combined with cisplatin is safe and reliable for non-small cell lung cancer and is especially suitable for non-squamous cell carcinoma chemotherapy.